Publications

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000

Loading…

2026

2323737 2RQKSFR5 2026 1 chicago-author-date-16th-edition 50 creator asc 1 1 319 https://isbscience.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22EKB49YA9%22%2C%22library%22%3A%7B%22id%22%3A2323737%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Deutsch%20et%20al.%22%2C%22parsedDate%22%3A%222026%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDeutsch%2C%20Eric%20W.%2C%20Cecilia%20Lindskog%2C%20Bogdan%20Budnik%2C%20Claudia%20Ctortecka%2C%20Tiannan%20Guo%2C%20Charles%20Pineau%2C%20Gong%20Zhang%2C%20et%20al.%202026.%20%26%23x201C%3BThe%202025%20Report%20on%20the%20Human%20Proteome%20from%20the%20HUPO%20Human%20Proteome%20Project.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Proteome%20Research%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facs.jproteome.5c00759%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facs.jproteome.5c00759%26lt%3B%5C%2Fa%26gt%3B.%20%26lt%3Ba%20title%3D%26%23039%3BCite%20in%20RIS%20Format%26%23039%3B%20class%3D%26%23039%3Bzp-CiteRIS%26%23039%3B%20data-zp-cite%3D%26%23039%3Bapi_user_id%3D2323737%26amp%3Bitem_key%3DEKB49YA9%26%23039%3B%20href%3D%26%23039%3Bjavascript%3Avoid%280%29%3B%26%23039%3B%26gt%3BCite%26lt%3B%5C%2Fa%26gt%3B%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%202025%20Report%20on%20the%20Human%20Proteome%20from%20the%20HUPO%20Human%20Proteome%20Project%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20W.%22%2C%22lastName%22%3A%22Deutsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecilia%22%2C%22lastName%22%3A%22Lindskog%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bogdan%22%2C%22lastName%22%3A%22Budnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Ctortecka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiannan%22%2C%22lastName%22%3A%22Guo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Pineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gong%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Andken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarissa%22%2C%22lastName%22%3A%22Zheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhi%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20M.%22%2C%22lastName%22%3A%22Mudge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Orchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20M.%22%2C%22lastName%22%3A%22Overall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolle%20H.%22%2C%22lastName%22%3A%22Packer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%20T.%22%2C%22lastName%22%3A%22Weintraub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20H.%20A.%22%2C%22lastName%22%3A%22Roehrl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Nice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20E.%22%2C%22lastName%22%3A%22Van%20Eyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Uwe%22%2C%22lastName%22%3A%22V%5Cu00f6lker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nuno%22%2C%22lastName%22%3A%22Bandeira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruedi%22%2C%22lastName%22%3A%22Aebersold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20L.%22%2C%22lastName%22%3A%22Moritz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilbert%20S.%22%2C%22lastName%22%3A%22Omenn%22%7D%5D%2C%22abstractNote%22%3A%22The%20HUPO%20Human%20Proteome%20Project%20%28HPP%29%20aims%20to%20complete%20the%20human%20protein%20parts%20list%20by%20detecting%20evidence%20of%20expression%20and%20of%20function%20for%20all%20proteins%20in%20the%20human%20proteome%2C%20and%20make%20proteomics%20an%20integral%20part%20of%20multiomics%20studies%20of%20health%20and%20disease.%20Here%20we%20describe%20the%20state%20of%20the%202025%20HPP%20reference%20proteome%20of%2019%2C435%20proteins%2C%20based%20on%20GENCODE%20v48%2C%20UniProtKB%202025_03%2C%20Human%20Protein%20Atlas%2024%2C%20MassIVE-KB%202023%2C%20and%20PeptideAtlas%202025-01.%20We%20evaluate%20the%20progress%20in%20the%20past%20year%2C%20with%2093.6%25%20of%20the%20proteome%20detected%2C%20and%20examine%20the%20proteins%20that%20have%20not%20yet%20been%20detected%20to%20determine%20where%20further%20progress%20can%20be%20made.%20We%20also%20evaluate%20the%20progress%20in%20determining%20at%20least%20one%20function%20for%20every%20protein%20in%20the%20HPP%20target%20list%2C%20finding%20an%20increase%20of%20288%20proteins%20in%20the%20highest%20category%20%28FE1%29%20to%205562.%20Finally%2C%20we%20provide%20highlights%20from%2012%20Biology%5C%2FDisease-based%20HPP%20initiatives%2C%20HPP%20resource%20pillars%2C%20and%20%5Cu03c0-HuB.%22%2C%22date%22%3A%222026%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1021%5C%2Facs.jproteome.5c00759%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facs.jproteome.5c00759%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221535-3893%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%222RQKSFR5%22%5D%2C%22dateModified%22%3A%222026-01-08T18%3A46%3A46Z%22%7D%7D%2C%7B%22key%22%3A%227H5E2AEG%22%2C%22library%22%3A%7B%22id%22%3A2323737%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22V%5Cu00e4nttinen%20et%20al.%22%2C%22parsedDate%22%3A%222026%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BV%26%23xE4%3Bnttinen%2C%20Ida%2C%20Joseph%20Saad%2C%20Tanja%20Ruokoranta%2C%20Guangrong%20Qin%2C%20Bahar%20Tercan%2C%20V%26%23xE9%3Bsteinn%20Thorsson%2C%20Sari%20Kyt%26%23xF6%3Bl%26%23xE4%3B%2C%20et%20al.%202026.%20%26%23x201C%3BDrivers%20of%20Clinical%20Resistance%20to%20Venetoclax%20and%20Hypomethylating%20Agents%20in%20Acute%20Myeloid%20Leukemia%20and%20Strategies%20for%20Improving%20Efficacy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BHemaSphere%26lt%3B%5C%2Fi%26gt%3B%2010%20%281%29%3A%20e70282.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fhem3.70282%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fhem3.70282%26lt%3B%5C%2Fa%26gt%3B.%20%26lt%3Ba%20title%3D%26%23039%3BCite%20in%20RIS%20Format%26%23039%3B%20class%3D%26%23039%3Bzp-CiteRIS%26%23039%3B%20data-zp-cite%3D%26%23039%3Bapi_user_id%3D2323737%26amp%3Bitem_key%3D7H5E2AEG%26%23039%3B%20href%3D%26%23039%3Bjavascript%3Avoid%280%29%3B%26%23039%3B%26gt%3BCite%26lt%3B%5C%2Fa%26gt%3B%20%20%26lt%3Ba%20title%3D%26%23039%3BDownload%26%23039%3B%20class%3D%26%23039%3Bzp-DownloadURL%20zp-getDownloadURL%26%23039%3B%20data-zp-dl%3D%26%23039%3Bapi_user_id%3D2323737%26amp%3Bdlkey%3DA3L785G5%26amp%3Bcontent_type%3Dapplication%5C%2Fpdf%26%23039%3B%20href%3D%26%23039%3Bjavascript%3Avoid%280%29%3B%26%23039%3B%26gt%3BDownload%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Drivers%20of%20clinical%20resistance%20to%20venetoclax%20and%20hypomethylating%20agents%20in%20acute%20myeloid%20leukemia%20and%20strategies%20for%20improving%20efficacy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ida%22%2C%22lastName%22%3A%22V%5Cu00e4nttinen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Saad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tanja%22%2C%22lastName%22%3A%22Ruokoranta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guangrong%22%2C%22lastName%22%3A%22Qin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bahar%22%2C%22lastName%22%3A%22Tercan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9steinn%22%2C%22lastName%22%3A%22Thorsson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sari%22%2C%22lastName%22%3A%22Kyt%5Cu00f6l%5Cu00e4%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pia%22%2C%22lastName%22%3A%22Ettala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anu%22%2C%22lastName%22%3A%22Partanen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marja%22%2C%22lastName%22%3A%22Py%5Cu00f6r%5Cu00e4l%5Cu00e4%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanna%22%2C%22lastName%22%3A%22Rimpil%5Cu00e4inen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timo%22%2C%22lastName%22%3A%22Siitonen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikko%22%2C%22lastName%22%3A%22Manninen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20J.%20M.%22%2C%22lastName%22%3A%22Valk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerwin%22%2C%22lastName%22%3A%22Huls%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%20A.%22%2C%22lastName%22%3A%22Heckman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mika%22%2C%22lastName%22%3A%22Kontro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heikki%22%2C%22lastName%22%3A%22Kuusanm%5Cu00e4ki%22%7D%5D%2C%22abstractNote%22%3A%22The%20B-cell%20lymphoma%202%20%28BCL-2%29%20inhibitor%20venetoclax%20%28VEN%29%20in%20combination%20with%20hypomethylating%20agents%20%28HMAs%29%20has%20improved%20treatment%20outcomes%20for%20acute%20myeloid%20leukemia%20%28AML%29%20patients%20unfit%20for%20intensive%20chemotherapy%20and%20is%20increasingly%20used%20in%20the%20relapsed%5C%2Frefractory%20setting.%20However%2C%20primary%20resistance%20remains%20a%20significant%20challenge%2C%20affecting%2020%25%5Cu201335%25%20of%20treatment-na%5Cu00efve%20and%20around%2050%25%20of%20previously%20treated%20AML%20patients.%20To%20investigate%20the%20mechanisms%20driving%20primary%20resistance%20to%20VEN%5Cu2013HMA%20therapy%2C%20we%20analyzed%20genetic%2C%20transcriptomic%2C%20BCL-2%20family%20protein%20expression%2C%20and%20ex%20vivo%20drug%20sensitivity%20data%20from%20101%20AML%20patients%20and%20correlated%20these%20profiles%20with%20clinical%20outcomes%20to%20VEN%5Cu2013HMA.%20Our%20study%20found%20that%20blasts%20from%20refractory%20patients%20exhibit%20an%20elevated%20BCL-XL%5C%2FBCL-2%20protein%20expression%20ratio%2C%20an%20immature%20CD34%2BCD38%5Cu2212%20phenotype%2C%20and%20frequent%20TP53%20mutations.%20Consistent%20with%20the%20high%20ratio%20of%20BCL-XL%5C%2FBCL-2%2C%20resistant%20samples%20showed%20increased%20ex%20vivo%20sensitivity%20to%20the%20dual%20BCL-2%5C%2FBCL-XL%20inhibitor%20navitoclax.%20In%20addition%2C%20SMAC%20mimetics%20were%20effective%20in%20refractory%20blasts%2C%20which%20correlated%20with%20high%20TNF%20gene%20expression%20in%20these%20cells.%20Ex%20vivo%20treatment%20with%20the%20combination%20of%20navitoclax%20and%20SMAC%20mimetics%20further%20enhanced%20the%20eradication%20of%20VEN%5Cu2013HMA%20refractory%20blasts%2C%20although%20toxicity%20was%20also%20observed%20in%20healthy%20CD34%2B%20cells.%20In%20conclusion%2C%20our%20integrative%20analysis%20identifies%20molecular%20signatures%20associated%20with%20primary%20VEN%5Cu2013HMA%20resistance%20and%20highlights%20BCL-2%5C%2FBCL-XL%20inhibition%20and%20SMAC%20mimetics%20as%20therapeutic%20strategies%20to%20target%20resistance.%22%2C%22date%22%3A%222026%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fhem3.70282%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1002%5C%2Fhem3.70282%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222572-9241%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%222RQKSFR5%22%5D%2C%22dateModified%22%3A%222026-01-16T20%3A52%3A23Z%22%7D%7D%5D%7D
Deutsch, Eric W., Cecilia Lindskog, Bogdan Budnik, Claudia Ctortecka, Tiannan Guo, Charles Pineau, Gong Zhang, et al. 2026. “The 2025 Report on the Human Proteome from the HUPO Human Proteome Project.” Journal of Proteome Research. http://doi.org/10.1021/acs.jproteome.5c00759. Cite
Vänttinen, Ida, Joseph Saad, Tanja Ruokoranta, Guangrong Qin, Bahar Tercan, Vésteinn Thorsson, Sari Kytölä, et al. 2026. “Drivers of Clinical Resistance to Venetoclax and Hypomethylating Agents in Acute Myeloid Leukemia and Strategies for Improving Efficacy.” HemaSphere 10 (1): e70282. http://doi.org/10.1002/hem3.70282. Cite Download